 The hits also undergo limited optimization to improve metabolic half life so that the compounds can be tested in animal models of disease and also to improve selectivity against other biological targets binding that may result in undesirable side effects.On average, only one in every 5,000 compounds that enters drug discovery to the stage of preclinical development becomes an approved drug.After hits are identified from a high throughput screen, the hits are confirmed and evaluated using the following methods